SCHEMBL648414

SCHEMBL648414

CCCCn1c(-c2cccc(OC)c2)nc(-c2ccccc2)c1CN(Cc1cccc(OCC)c1)Cc1cccc(OCC)c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TLR7 Q9NYK1 1/20 0.45
MAPT P10636 2/20 0.41
C5AR1 P21730 1/20 0.41
HSP90AA1 P07900 1/20 0.40
HSP90AB1 P08238 1/20 0.40
CALM1 P0DP23 1/20 0.39
CAMKK2 Q96RR4 1/20 0.39
CACNA2D1 P54289 1/20 0.38
CNR2 P34972 1/20 0.38
USP2 O75604 4/20 0.38
ALDH1A1 P00352 4/20 0.38
CYP3A4 P08684 4/20 0.38
CYP1A2 P05177 3/20 0.38
CYP2C9 P11712 3/20 0.38
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
HSD17B10 Q99714 2/20 0.38
CASP1 P29466 2/20 0.38
CASP7 P55210 2/20 0.38
HPGD P15428 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1913028 0.96 TLR7 (0.43) TLR7MAPTC5AR1HSP90AA1HSP90AB1
SCHEMBL649083 0.94 C5AR1 (0.42) TLR7MAPTC5AR1HSP90AA1HSP90AB1
SCHEMBL652044 0.93 C5AR1 (0.43) TLR7MAPTC5AR1HSP90AA1HSP90AB1
SCHEMBL649417 0.93 C5AR1 (0.43) TLR7MAPTC5AR1CACNA2D1ALDH1A1
SCHEMBL649258 0.93 C5AR1 (0.45) TLR7MAPTC5AR1CACNA2D1ALDH1A1
SCHEMBL5135433 0.92 C5AR1 (0.46) TLR7MAPTC5AR1HSP90AA1HSP90AB1
SCHEMBL650569 0.91 C5AR1 (0.44) TLR7MAPTC5AR1CACNA2D1HPGD
SCHEMBL650505 0.90 C5AR1 (0.43) MAPTC5AR1CACNA2D1ALDH1A1HSD17B10
SCHEMBL650373 0.90 TP53 (0.41) TLR7MAPTC5AR1ALDH1A1HSD17B10
SCHEMBL648091 0.89 C5AR1 (0.44) MAPTC5AR1HSD17B10BCHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8119665-B2 Aryl imidazoles and related compounds as C5a receptor modulators NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2012-02-21 US disclosed
US-8119665-B2 Aryl imidazoles and related compounds as C5a receptor modulators NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2012-02-21 US disclosed
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
US-7186734-B2 Aryl imidazoles and related compounds as C5a receptor modulators NEUROGEN CORPORATION (US) 2007-03-06 US disclosed
US-7186734-B2 Aryl imidazoles and related compounds as C5a receptor modulators NEUROGEN CORPORATION (US) 2007-03-06 US disclosed
US-7186734-B2 Aryl imidazoles and related compounds as C5a receptor modulators NEUROGEN CORPORATION (US) 2007-03-06 US disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed